Exclusive writer: Blood products with scarce raw materials are first collected!

The largest inter-provincial alliance with large-scale procurement—the 11-province joint centralized procurement in Guangdong included blood products for the first time, which aroused great attention in the industry, resulting in huge fluctuations and a series of reactions in the capital market
.

Due to the scarcity of raw materials, it is difficult for blood products to replicate the “quantity-for-price” logic of generic drugs.

How big is the drop in the price of centralized collection of blood products? What is the status of the industry? How will the market landscape change in the future?

On March 10 and 11, the Guangdong Provincial Drug Trading Center successively released two proposed/alternative result documents for procurement with volume
.

This centralized procurement alliance involves 11 provinces including Shanxi, Jiangxi, Henan, and Guangxi, and is hailed by the industry as the largest inter-provincial alliance for large-scale procurement

This time, the centralized procurement alliance has attracted much attention not only because of its size, but also because two varieties of growth hormone and blood products entered the centralized procurement for the first time.

After the announcement, it caused huge fluctuations and a series of reactions in the capital market

The blood products collected this time involved five varieties of intravenous injection of human immunoglobulin (pH4), human immunoglobulin, human coagulation factor VIII, human fibrinogen, and human albumin
.

According to the PDB database, the sales of these five varieties in sample hospitals in 2021 are expected to be 8.
44 billion yuan

Looking at this centralized procurement, after the release of the “Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement Documents” on January 19, on February 23, the Guangdong Provincial Drug Trading Center released two batches of registered products that meet the application conditions and price declaration regulations.

Information for business inquiries and verification

The following is an analysis of the domestic market of blood products and the registered enterprises based on the specific information of this collection, combined with the relevant statistics of the PDB database
.

0 1

Intravenous human immunoglobulin (pH4) and human immunoglobulin:When the 2 billion battle is going on

According to the PDB database, the sales of human immunoglobulin and intravenous human immunoglobulin (pH4) in sample hospitals nationwide in 2020 will be 1.

734 billion yuan, and the sales in the first three quarters of 2021 will be 1.
482 billion yuan.
2 billion yuan

Intravenous human immunoglobulin (pH4) and human immunoglobulin are immune stimulants, intravenous human immunoglobulin (pH4) treatment of primary immunoglobulin deficiency, neonatal sepsis, severe primary immune thrombocytopenia The indications for the disease, Kawasaki disease, generalized myasthenia gravis and acute Guillain-Barre syndrome, as well as the indications for the prevention and treatment of measles and infectious hepatitis contacts with human immunoglobulin have been included in the national medical insurance category B list.

It belongs to the varieties with large consumption and high purchase amount, and its average unit price has remained basically the same in the past three years

5 provinces and regions account for about 1/4 of the country's sales

The alliances participating in the collection and reporting of the drug collection involved 11 provinces and regions, including Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, and Xinjiang Production and Construction Corps
.

The PDB database shows that, by city sales, intravenous injection of human immunoglobulin (pH4) and human immunoglobulin in the first three quarters of 2021 for sample hospitals in 5 provinces (data not shown in the remaining 6 provinces) The total sales amounted to 371 million yuan, accounting for 25.
03% of the country's sales, and 26.
08% of the country's sales volume , accounting for about a quarter of the country's total

Judging from the list published in the report list, the intravenous injection of human immunoglobulin (pH4) and human immunoglobulin centralized collection involves nearly 30 companies, including Shanghai RAAS Blood Products, Hualan Bioengineering Chongqing, Shandong Taibang Biological products, Sichuan Yuanda Shuyang Pharmaceutical Co.
, Ltd.
, and Guizhou Taibang Biological Products are in the leading position
.

The highest selling price is 728 yuan

It can be seen from the PDB database that in the first three quarters of 2021, the two companies of Taibang, Shandong Taibang Biological Products and Guizhou Taibang Biological Products, accounted for 28.
76% of the national sample hospital sales, Sichuan Yuanda Shuyang Pharmaceutical accounted for 13.
64%, Hualan The two companies, Hualan Bioengineering Co.
, Ltd.
and Hualan Bioengineering Chongqing, account for 11.
82%, and Chengdu Rongsheng Pharmaceutical Co.
, Ltd.
accounts for 10.
76%
.
Most of the manufacturers' unit prices are around 600 yuan, the highest is 728.
26 yuan from Harbin Pasifico Bio, and the lowest is 219.
0 yuan from Sinopharm Shanghai Blood Products, but there are only two in excess
.

This centralized procurement also announced the highest effective declared price/highest average daily cost of 276 drugs.
Different specifications of intravenous human immunoglobulin (pH4) and human immunoglobulin also have different highest effective declared prices.
From the price comparison It can be seen that only the average unit price of 0.
15g of human immunoglobulin of Guangdong Shuanglin Biopharmaceuticals is 577.
76 yuan, which is obviously the highest effective declared price, and all specifications of other companies are lower than the highest effective declared price
.

Freeze-dried 2.
5g specification only one company signed up

Judging from the registration situation of enterprises announced on February 23, there are many enterprises applying for intravenous injection of human immunoglobulin (pH4) 5% (50ml: 2.
5g), and there are also Boya Biopharmaceuticals that are not displayed in the above sample hospitals.
Group, Guangdong Shuanglin Bio, Sinopharm Shanghai Blood Products, Hebei Daan Pharmaceutical, Lanzhou Lansheng Blood Products, Shenzhen Weiguang Biological Products, Xinjiang Deyuan Bioengineering, Zhengzhou Raishi Blood Products 8 enterprises; 5% (25ml: 1.
25g) specification is also registered by Shenzhen Weiguang Biological Products; while the 5% (100ml:5g) specification is only registered by Chengdu Rongsheng Pharmaceutical Co.
, Ltd.
, and several companies with large sales such as Shandong Taibang Biological Products, Boya Biopharmaceuticals The Group and Sichuan Yuanda Shuyang Pharmaceutical did not sign up
.
Human immunoglobulin 10% (3ml:0.
3g) specifications also registered Guangdong Danxia Biopharmaceuticals, Guangdong Weilun Biopharmaceuticals, Hebei Daan Pharmaceuticals, Tonglu Biopharmaceuticals, 10% (1.
5ml:0.
15g) specifications registered There are also Hebei Daan Pharmaceutical and Hualan Bioengineering Co.
,
Ltd.
Only one company of Guangdong Weilun Biopharmaceuticals has registered for the lyophilized intravenous injection of human immunoglobulin (pH4) 2.
5g, and several companies with large sales, such as Boya Biopharmaceutical Group and Shenzhen Weiguang Biological Products, have not yet registered
.

0 2

Human clotting factors:

Foreign companies grab 840 million cakes

According to the PDB database, the sales of the whole human coagulation factor VIII in the national sample hospitals in 2020 will be 769 million yuan, and the sales in the first three quarters of 2021 will be 629 million yuan, which is expected to be close to 840 million yuan for the whole year
.

5 provinces and regions have more than half of the country's sales

Human coagulation factor VIII is listed in the national medical insurance category A list, and the indications of recombinant human coagulation factor VIII for the treatment of children with hemophilia A (A) and adult hemophilia A (A) bleeding have been included in the national medical insurance category B catalog.
The three-year average unit price and sample hospital sales both rose slightly
.

The PDB database shows that by city sales, the total sales of human coagulation factor VIII in the first three quarters of 2021 of the sample hospitals in 5 provinces (no data are shown in the remaining 6 provinces) are 332 million yuan.
It accounts for 51.
39% of the whole country, the sales volume has exceeded half of the whole country, and the sales volume accounts for 43.
84% of the whole country
.

The highest selling price is 7.
9 times the lowest

Judging from the list published in the detailed list of reported quantities, 6 companies were involved in the centralized procurement of human coagulation factor VIII, among which Shandong Taibang Biological Products, Shanghai RAAS Blood Products, and Hualan Bioengineering Co.
, Ltd.
ranked the top three
.

It can be seen from the PDB database that in the first three quarters of 2021, two foreign companies, Bayer and Baxter, accounted for 71.
98% of the total sales of sample hospitals nationwide, and the unit price was significantly higher than that of domestic companies.
Shanghai RAAS accounted for 9.
84% and Shandong Taibang accounted for 9.
26%.
%, the average unit price is around 400 yuan
.
The highest price is 3065.
53 yuan in Pfizer Europe, the lowest is 387.
81 yuan in Shandong Taibang, and the highest price is 7.
9 times the lowest
.

This centralized procurement also announced the highest effective declared price/highest average daily cost of 276 drugs.
Different specifications of human coagulation factor VIII also have different highest effective declared prices.
From the price comparison, only Guangdong Shuanglin Biopharmaceuticals has a 200IU specification.
The unit price of human coagulation factor VIII is 420.
11 yuan, which is slightly higher than the highest effective declared price, and all specifications of other enterprises are lower than the highest effective declared price
.

According to the registration situation of enterprises announced on February 23, there are only two registrations for the 300IU specification of human coagulation factor VIII; in addition to the 6 companies listed above for the 200IU specification, there are Nanyue Biopharmaceutical and Xikangbao biological products that are not displayed in the above sample hospitals.
, the recombinant human coagulation factor VIII is not included in the list of collection and reporting
.

0 3

Human Fibrinogen:

The top three products monopolize the nearly 600 million market

According to the PDB database, the sales of human fibrinogen in sample hospitals across the country in 2020 will be 505 million yuan, and the sales in the first three quarters of 2021 will be 443 million yuan, which is expected to be close to 600 million yuan for the whole year
.

The sales and quantity of 5 provinces and regions account for about 1/4 of the country

The indication of human fibrinogen in the treatment of active bleeding caused by hypofibrinogenemia has been included in the national medical insurance category B catalog.
The sales of sample hospitals in the past three years have increased slightly, while the average unit price has decreased slightly
.

According to the PDB database, the sales of human fibrinogen in the first three quarters of 2021 totaled 106 million yuan in the first three quarters of 2021 for the sample hospitals of human fibrinogen in 5 provinces and autonomous regions (data not shown in the remaining 6 provinces and autonomous regions) .
It accounts for 24.
03% of the national total, and the sales volume accounts for 23.
79% of the national total
.

The top three products account for nearly 95% of the country

Judging from the list published in the report list, the collection of human fibrinogen involved 7 companies, of which Boya Biopharmaceutical Group, Shanghai RAAS Blood Products, and Shandong Taibang Biological Products ranked the top three
.

According to the PDB database, in the first three quarters of 2021, Boya Biopharmaceutical Group, Shanghai RAAS Blood Products and Shandong Taibang Biopharmaceuticals accounted for 94.
80% of the top three sales.
The three basically monopolized the market, with an average unit price of 840~960 yuan.
between
.

This centralized procurement announced the highest effective declared price/highest average daily cost of 276 drugs, and human fibrinogen also has the highest effective declared price.
From the price comparison, only Harbin Pasifico Bio 0.
5g human fibrinogen The unit price of 956.
42 yuan is slightly higher than the highest valid declared price, and all specifications of other enterprises are lower than the highest valid declared price
.

According to the registration situation of enterprises announced on February 23, the specification of human fibrinogen is only 0.
5g.
In addition to the 7 companies in the above-mentioned list, there is also Sichuan Grand Shuyang Pharmaceutical Co.
, Ltd.
, which is not displayed for sale in the above-mentioned sample hospitals
.

0 4

Human albumin:

Heroes are fighting for 5 billion

According to the PDB database, the sales of human albumin in sample hospitals across the country in 2020 will be 4.
218 billion yuan, and the sales in the first three quarters of 2021 will be 3.
708 billion yuan, which is expected to be close to 5 billion yuan for the whole year
.

5 provinces and regions account for about 1/5 of the country's top sales

The indications of human serum albumin for the treatment of patients with rescue, severe or pleural and ascites caused by liver cirrhosis and cancer and albumin less than 30g/L have been included in the national medical insurance category B catalog, which belongs to the category of large consumption and high purchase amount.
It can be seen that the average unit price in the past three years is basically the same, while the sales of sample hospitals have increased slightly
.

The PDB database shows that by city sales, the total sales of human albumin in the first three quarters of 2021 of the sample hospitals in 5 provinces (no data are shown in the remaining 6 provinces) are 799 million yuan, and the sales It accounts for 21.
56% of the national total, and the sales volume accounts for 22.
56% of the national total, accounting for about one-fifth of the national total
.

Judging from the list published in the report list, the collection of human albumin involves nearly 40 companies, including Swiss Jet Behring Biological Products, Spain's Instituto Grifols SA, Germany's CSL Behring GmbH, American Grifols Biologicals LLC, Baxalta US Inc, Austrian Baxter AG, Shandong Taibang Biological Products, and Hualan Bioengineering were in the leading position
.

The highest selling price is 2.
25 times the lowest

It can be seen from the PDB database that in the first three quarters of 2021, the two companies CSL Behring accounted for 31.
80% of the national sample hospital sales, Grifols accounted for 22.
21%, Baxter accounted for 19.
31%, Shandong Taibang biological products accounted for 7.
96% %, Octapharma accounted for 4.
63%, and these companies accounted for 85.
91%, occupying the main market
.
The average unit price of each manufacturer is between 220-500 yuan, the highest is Baxter Healthcare's 506.
26 yuan, the lowest is Hualan Bioengineering (Suzhou) 224.
98 yuan, the highest price is 2.
25 times the lowest
.

This centralized procurement announced the highest effective declared price/highest daily average cost of 276 drugs, and human albumin also has the highest effective declared price, and all specifications of each enterprise are lower than the highest effective declared price
.

According to the company registration situation announced on February 23, there are many companies that have signed up for the human albumin 20% (50ml:10g) specification.
In addition, there are Swiss Jet Behring biological products that are not displayed for sale in the above sample hospitals, Germany Octapharma, baxalta US (a US company spun off from Baxter), Guangdong Danxia Biopharmaceutical, Hebei Daan Pharmaceutical, Grifols Biologicals LLC, Grifols Therapeutics LLC, Xinjiang Deyuan Bioengineering, Zhengzhou RAAS Blood Products; 20 % (25ml: 5g) specifications are also registered by Hebei Daan Pharmaceutical; and 25% (50ml: 12.
5g) specifications are only registered by Chengdu Rongsheng Pharmaceutical, which is not in the above list, and several companies with large sales such as Baxter Healthcare , Grifols Biologicals and Octapharma, etc.
have not registered
.

summary

The market size of the centralized procurement (calculated according to the highest declared price) is about 3.
08 billion yuan, of which intravenous injection of human immunoglobulin (pH4), human immunoglobulin, human coagulation factor VIII, human fibrinogen and human serum albumin pre-treatment.
The purchase volume (converted to standard specifications) was 914,000 bottles, 13.
145 million bottles, 290,000 bottles, 150,000 bottles and 3.
079 million bottles , accounting for 7.
7%, 0.
1%, 17.
0%, 12.
8% and 4.
7%, the market size calculated according to the highest declared price is 840 million yuan, 363,000 yuan, 120 million yuan, 140 million yuan and 1.
86 billion yuan respectively
.

Due to the scarcity of raw materials for blood products, it is difficult to replicate the "quantity-for-price" logic of generic drugs
.
In this centralized collection, blood products are listed separately, and the bid-winning rules are mild and no bidding is required: the quotations for the products declared by the enterprise and other products only need to be ≤ the lowest value between the highest effective declared price and the lowest price in the enterprise alliance area.
You can enter the list to be selected and obtain 100% of the first-year pre-purchase volume of the company in the alliance area, without bidding
.
Therefore, in theory, blood product companies can be selected at a price not higher than the lowest price in the enterprise alliance area, and the price reduction range is controllable
.

After blood products are included in the centralized collection, on the one hand, it is expected to reduce the burden on sales terminals, reduce sales expenses, and help related companies to improve quality and efficiency; Enterprises are more moderate, and as market demand is still expanding rapidly, batches are expected to continue to increase
.
In the long run, the blood products industry still has good growth potential
.

Text editor: Zhang Jieyun

Format editor: Yu Chenglin